English

Pear Therapeutics, Inc.

EDGAR

Annual report (10-K) · filed 2023-03-31

12 filing records in this dataset, filed from 2021-01-15 to 2023-03-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

2.57 million USD

2022 Q4 · USD

Exact inputs and evidence

Revenue: 12694000 USD Source
Revenue: 10129000 USD Source

Operating margin

-1,136.84%

2022 Q4 · %

Exact inputs and evidence

Operating Income: -123350000 USD Source
Operating Income: -94190000 USD Source
Revenue: 12694000 USD Source
Revenue: 10129000 USD Source

Operating cash flow

-24.3 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -113895000 USD Source
Operating Cash Flow: -89615000 USD Source

Free cash flow

-25.4 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -113895000 USD Source
Operating Cash Flow: -89615000 USD Source
Capital Expenditure: 3470000 USD Source
Capital Expenditure: 2400000 USD Source

Cash and cash equivalents: 48.3 million USD 2022-12-31 Source
Exact value

48301000 USD
Long-term debt including current maturities: 38.3 million USD 2022-12-31
Exact inputs and evidence

38292000 USD

Long-term debt including current maturities: 38292000 USD Source
Shares outstanding: 140 million shares 2022-12-31 Source
Exact value

140454086 shares

Reported share-count change

1.90% · 2.62 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

137836028 shares · 2021-12-31· Source
140454086 shares · 2022-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

12.7 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Revenue: 2749000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 3297000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 4083000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 12694000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 10129000 USD · 2022-01-01 – 2022-09-30 Source

Net income

-75.5 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Net income: -23859000 USD · 2022-01-01 – 2022-03-31 Source
Net income: 5462000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -30723000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -75491000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -49120000 USD · 2022-01-01 – 2022-09-30 Source

Operating cash flow

-114 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -36708000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -66345000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -36708000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -89615000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -66345000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -113895000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -89615000 USD · 2022-01-01 – 2022-09-30 Source

Capital expenditure

3.47 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Capital expenditure: 501000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1820000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 501000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2400000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1820000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3470000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2400000 USD · 2022-01-01 – 2022-09-30 Source

Free cash flow

-117 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -36708000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -66345000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -36708000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -89615000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -66345000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -113895000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -89615000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 501000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 1820000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 501000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2400000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1820000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3470000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 2400000 USD · 2022-01-01 – 2022-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-03-31.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2022-12-31
Operating income: 4 of 11 periods available· newest 2022-12-31
Net income: 4 of 11 periods available· newest 2022-12-31
Operating cash flow: 4 of 11 periods available· newest 2022-12-31
Capital expenditure: 4 of 11 periods available· newest 2022-12-31
Total assets: 4 of 11 periods available· newest 2022-12-31
Total liabilities: 4 of 11 periods available· newest 2022-12-31
Current assets: 4 of 11 periods available· newest 2022-12-31
Current liabilities: 4 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2022-12-31
Shares outstanding: 4 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+201.7%

Prior period

USD 4.21 million

2021-01-01 – 2021-12-31
Current period

USD 12.69 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

12694000 − 4208000 = 8486000 USD

4208000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
12694000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Year-over-year change in Revenue: 8486000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 12694000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1336052 Filing: 000183556723000018 Input fundies:Revenue: 4208000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1336762 Filing: 000183556723000018
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 10.35 million

Prior period

−USD 65.14 million

2021-01-01 – 2021-12-31
Current period

−USD 75.49 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-75491000 − -65142000 = -10349000 USD

-65142000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-75491000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Year-over-year change in Net income: -10349000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -75491000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1584448 Filing: 000183556723000018 Input fundies:NetIncome: -65142000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1495840 Filing: 000183556723000018
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.85 million

Prior period

−USD 109.04 million

2021-01-01 – 2021-12-31
Current period

−USD 113.9 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-113895000 − -109043000 = -4852000 USD

-109043000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-113895000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Year-over-year change in Operating cash flow: -4852000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -113895000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1523967 Filing: 000183556723000018 Input fundies:OperatingCashFlow: -109043000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1524674 Filing: 000183556723000018
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+5.9%

Prior period

USD 3.28 million

2021-01-01 – 2021-12-31
Current period

USD 3.47 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

3470000 − 3278000 = 192000 USD

3278000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
3470000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Year-over-year change in Capital expenditure: 192000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3470000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529294 Filing: 000183556723000018 Input fundies:CapitalExpenditure: 3278000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529938 Filing: 000183556723000018
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 12.69 million 100% of revenue
Cost of revenue USD 8.18 million 64% of revenue
Operating expenses USD 127.86 million 1,007% of revenue
Operating income −USD 123.35 million −972% of revenue
Tax, interest and other Derived −USD 47.86 million −377% of revenue
Net income −USD 75.49 million −595% of revenue

Cash

Operating cash flow −USD 113.9 million −897% of revenue
Capital expenditure USD 3.47 million 27% of revenue
Free cash flow Derived −USD 117.37 million −925% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 197% of revenue.
2020 Operating loss: operating costs were 917% of revenue.
2021 Operating loss: operating costs were 2,612% of revenue.
2022 Operating loss: operating costs were 1,072% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	32562000	64165000 Derived	-31603000	-22269000 Derived	-9334000	-36877000 Derived	Source 2019-01-01 – 2019-12-31: 32562000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -31603000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -9334000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -36596000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 281000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	9384000	86028000 Derived	-76644000	20379000 Derived	-97023000	-71794000 Derived	Source 2020-01-01 – 2020-12-31: 9384000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -76644000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -97023000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -67894000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3900000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	4208000	109893000 Derived	-105685000	-40543000 Derived	-65142000	-112321000 Derived	Source 2021-01-01 – 2021-12-31: 4208000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -105685000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -65142000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -109043000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3278000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	12694000	136044000 Derived	-123350000	-47859000 Derived	-75491000	-117365000 Derived	Source 2022-01-01 – 2022-12-31: 12694000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -123350000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -75491000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -113895000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3470000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 12.7M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	32562000	Revenue: 32562000 Open source
20202020-12-31	Revenue	9384000	Revenue: 9384000 Open source
20212021-12-31	Revenue	4208000	Revenue: 4208000 Open source
20222022-12-31	Revenue	12694000	Revenue: 12694000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

201.7% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 32562000 Open source
20202020-12-31	Year over year	-71.2%	Revenue: 9384000 Open source Revenue: 32562000 Open source
20212021-12-31	Year over year	-55.2%	Revenue: 4208000 Open source Revenue: 9384000 Open source
20222022-12-31	Year over year	201.7%	Revenue: 12694000 Open source Revenue: 4208000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -971.7% 2022

Net margin -594.7% 2022

Free cash flow margin -924.6% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-97.1%	Operating Income: -31603000 Open source Revenue: 32562000 Open source
20202020-12-31	Operating margin	-816.8%	Operating Income: -76644000 Open source Revenue: 9384000 Open source
20212021-12-31	Operating margin	-2,511.5%	Operating Income: -105685000 Open source Revenue: 4208000 Open source
20222022-12-31	Operating margin	-971.7%	Operating Income: -123350000 Open source Revenue: 12694000 Open source
20192019-12-31	Net margin	-28.7%	Net Income: -9334000 Open source Revenue: 32562000 Open source
20202020-12-31	Net margin	-1,033.9%	Net Income: -97023000 Open source Revenue: 9384000 Open source
20212021-12-31	Net margin	-1,548.1%	Net Income: -65142000 Open source Revenue: 4208000 Open source
20222022-12-31	Net margin	-594.7%	Net Income: -75491000 Open source Revenue: 12694000 Open source
20192019-12-31	Free cash flow margin	-113.3%	Revenue: 32562000 Open source Operating Cash Flow: -36596000 Open source Capital Expenditure: 281000 Open source
20202020-12-31	Free cash flow margin	-765.1%	Revenue: 9384000 Open source Operating Cash Flow: -67894000 Open source Capital Expenditure: 3900000 Open source
20212021-12-31	Free cash flow margin	-2,669.2%	Revenue: 4208000 Open source Operating Cash Flow: -109043000 Open source Capital Expenditure: 3278000 Open source
20222022-12-31	Free cash flow margin	-924.6%	Revenue: 12694000 Open source Operating Cash Flow: -113895000 Open source Capital Expenditure: 3470000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -113.9M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-36596000	Operating Cash Flow: -36596000 Open source
20202020-12-31	Operating cash flow	-67894000	Operating Cash Flow: -67894000 Open source
20212021-12-31	Operating cash flow	-109043000	Operating Cash Flow: -109043000 Open source
20222022-12-31	Operating cash flow	-113895000	Operating Cash Flow: -113895000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -117.4M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-36877000	Operating Cash Flow: -36596000 Open source Capital Expenditure: 281000 Open source
20202020-12-31	Free cash flow	-71794000	Operating Cash Flow: -67894000 Open source Capital Expenditure: 3900000 Open source
20212021-12-31	Free cash flow	-112321000	Operating Cash Flow: -109043000 Open source Capital Expenditure: 3278000 Open source
20222022-12-31	Free cash flow	-117365000	Operating Cash Flow: -113895000 Open source Capital Expenditure: 3470000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

67.8% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	28.2%	Total Liabilities: 30908000 Open source Total Assets: 109692000 Open source
20202020-12-31	Liabilities / assets	34.2%	Total Liabilities: 45250000 Open source Total Assets: 132366000 Open source
20212021-12-31	Liabilities / assets	54.1%	Total Liabilities: 106726000 Open source Total Assets: 197160000 Open source
20222022-12-31	Liabilities / assets	67.8%	Total Liabilities: 64544000 Open source Total Assets: 95129000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.48× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	6.26×	Current Assets: 106978000 Open source Current Liabilities: 17101000 Open source
20202020-12-31	Current assets / current liabilities	3.1×	Current Assets: 126057000 Open source Current Liabilities: 40686000 Open source
20212021-12-31	Current assets / current liabilities	3.93×	Current Assets: 185241000 Open source Current Liabilities: 47166000 Open source
20222022-12-31	Current assets / current liabilities	1.48×	Current Assets: 72959000 Open source Current Liabilities: 49442000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 9.33 million Exact value Exact value: -9334000 USD 2019-01-01 – 2019-12-31: -9334000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pear Therapeutics, Inc. · 2019-12-31 Pear Therapeutics, Inc. (edgar:1835567) Net Income: -9334000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9334000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000162828021025559/pear-20211223.htm#4521612 Filing: 000162828021025559 The citation records this snapshot. The page link may show a newer release later.	−USD 36.6 million Exact value Exact value: -36596000 USD 2019-01-01 – 2019-12-31: -36596000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pear Therapeutics, Inc. · 2019-12-31 Pear Therapeutics, Inc. (edgar:1835567) Operating Cash Flow: -36596000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36596000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000162828021025559/pear-20211223.htm#3711616 Filing: 000162828021025559 The citation records this snapshot. The page link may show a newer release later.	USD 281,000 Exact value Exact value: 281000 USD 2019-01-01 – 2019-12-31: 281000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pear Therapeutics, Inc. · 2019-12-31 Pear Therapeutics, Inc. (edgar:1835567) Capital Expenditure: 281000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 281000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000162828021025559/pear-20211223.htm#3721161 Filing: 000162828021025559 The citation records this snapshot. The page link may show a newer release later.	−USD 36.88 million Calculation and evidence -36596000 − 281000 USD Exact free cash flow: -36877000 USD 2019-01-01 – 2019-12-31: -36596000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 281000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pear Therapeutics, Inc. · 2019-12-31 Pear Therapeutics, Inc. (edgar:1835567) Free cash flow: -36877000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36596000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000162828021025559/pear-20211223.htm#3711616 Filing: 000162828021025559 Input fundies:CapitalExpenditure: 281000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000162828021025559/pear-20211223.htm#3721161 Filing: 000162828021025559 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 97.02 million Exact value Exact value: -97023000 USD 2020-01-01 – 2020-12-31: -97023000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pear Therapeutics, Inc. · 2020-12-31 Pear Therapeutics, Inc. (edgar:1835567) Net Income: -97023000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97023000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000010/pear-20211231.htm#2457669 Filing: 000183556722000010 The citation records this snapshot. The page link may show a newer release later.	−USD 67.89 million Exact value Exact value: -67894000 USD 2020-01-01 – 2020-12-31: -67894000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pear Therapeutics, Inc. · 2020-12-31 Pear Therapeutics, Inc. (edgar:1835567) Operating Cash Flow: -67894000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -67894000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000010/pear-20211231.htm#1584225 Filing: 000183556722000010 The citation records this snapshot. The page link may show a newer release later.	USD 3.9 million Exact value Exact value: 3900000 USD 2020-01-01 – 2020-12-31: 3900000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pear Therapeutics, Inc. · 2020-12-31 Pear Therapeutics, Inc. (edgar:1835567) Capital Expenditure: 3900000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000010/pear-20211231.htm#1591510 Filing: 000183556722000010 The citation records this snapshot. The page link may show a newer release later.	−USD 71.79 million Calculation and evidence -67894000 − 3900000 USD Exact free cash flow: -71794000 USD 2020-01-01 – 2020-12-31: -67894000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3900000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pear Therapeutics, Inc. · 2020-12-31 Pear Therapeutics, Inc. (edgar:1835567) Free cash flow: -71794000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -67894000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000010/pear-20211231.htm#1584225 Filing: 000183556722000010 Input fundies:CapitalExpenditure: 3900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556722000010/pear-20211231.htm#1591510 Filing: 000183556722000010 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 65.14 million Exact value Exact value: -65142000 USD 2021-01-01 – 2021-12-31: -65142000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pear Therapeutics, Inc. · 2021-12-31 Pear Therapeutics, Inc. (edgar:1835567) Net Income: -65142000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65142000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1495840 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	−USD 109.04 million Exact value Exact value: -109043000 USD 2021-01-01 – 2021-12-31: -109043000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pear Therapeutics, Inc. · 2021-12-31 Pear Therapeutics, Inc. (edgar:1835567) Operating Cash Flow: -109043000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109043000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1524674 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	USD 3.28 million Exact value Exact value: 3278000 USD 2021-01-01 – 2021-12-31: 3278000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pear Therapeutics, Inc. · 2021-12-31 Pear Therapeutics, Inc. (edgar:1835567) Capital Expenditure: 3278000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3278000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529938 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	−USD 112.32 million Calculation and evidence -109043000 − 3278000 USD Exact free cash flow: -112321000 USD 2021-01-01 – 2021-12-31: -109043000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3278000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pear Therapeutics, Inc. · 2021-12-31 Pear Therapeutics, Inc. (edgar:1835567) Free cash flow: -112321000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109043000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1524674 Filing: 000183556723000018 Input fundies:CapitalExpenditure: 3278000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529938 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 75.49 million Exact value Exact value: -75491000 USD 2022-01-01 – 2022-12-31: -75491000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Net Income: -75491000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -75491000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1584448 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	−USD 113.9 million Exact value Exact value: -113895000 USD 2022-01-01 – 2022-12-31: -113895000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Operating Cash Flow: -113895000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -113895000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1523967 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	USD 3.47 million Exact value Exact value: 3470000 USD 2022-01-01 – 2022-12-31: 3470000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Capital Expenditure: 3470000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3470000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529294 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.	−USD 117.37 million Calculation and evidence -113895000 − 3470000 USD Exact free cash flow: -117365000 USD 2022-01-01 – 2022-12-31: -113895000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3470000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pear Therapeutics, Inc. · 2022-12-31 Pear Therapeutics, Inc. (edgar:1835567) Free cash flow: -117365000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T05:52:41Z Snapshot: 5800922346120830c9b4afd19c3818bbde97db7c8fe7322315ad1295a3e4e7d8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1835567?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -113895000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1523967 Filing: 000183556723000018 Input fundies:CapitalExpenditure: 3470000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm#1529294 Filing: 000183556723000018 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

12 filings · 748 latest values · 748 originally reported values

Dataset published 2026-11-09. Source filing dates and reporting periods are shown separately.

Identifiers: 0001835567, 1835567, edgar:1835567

Also known as PEAR THERAPEUTICS, INC., Pear Therapeutics, Inc., Thimble Point Acquisition Corp.

Pear Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation